| association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE pos logIC50 MEAN |
FEATURE neg logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
ANOVA Tissue pval |
ANOVA MSI pval |
ANOVA FEATURE %FDR |
a1 |
gain_cnaBRCA26_(CDK12,ERBB2,MED24) |
1377 |
|
1 |
Afatinib (rescreen) |
ERBB2, EGFR |
15 |
32 |
2.3 |
0.704 |
3.83 |
-3.13 |
2.3 ** |
2.3 ** |
2.4 ** |
2.07e-09 |
NA |
NA |
0.0024 |
a2 |
gain_cnaBRCA27_(CLTC,PPM1D) |
119 |
|
1 |
Lapatinib |
ERBB2, EGFR |
3 |
10 |
0.693 |
-2.2 |
2.54 |
-4.74 |
5.7 ** |
6.1 ** |
4.6 ** |
2.92e-06 |
NA |
NA |
1.7 |
a3 |
gain_cnaBRCA26_(CDK12,ERBB2,MED24) |
255 |
|
1 |
CP724714 |
ERBB2 |
14 |
34 |
2.33 |
2.27 |
4.44 |
-2.17 |
1.6 * |
2.2 ** |
1.1 * |
6.72e-06 |
NA |
NA |
2 |
a4 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
204 |
|
1 |
Tipifarnib |
Farnesyl-transferase (FNTA) |
5 |
43 |
2.77 |
4.24 |
1.31 |
2.93 |
2.4 ** |
2.5 ** |
1.7 * |
6.77e-06 |
NA |
NA |
2 |
a5 |
gain_cnaBRCA39_(FOXA1,NKX2-1,PSMA6) |
159 |
|
1 |
HG-6-64-1 |
BRAFV600E, TAK, MAP4K5 |
7 |
39 |
1.63 |
4.09 |
1.55 |
2.54 |
1.9 * |
1.9 * |
2.3 ** |
2.3e-05 |
NA |
NA |
5.1 |
a6 |
loss_cnaBRCA33 |
206 |
|
1 |
Ruxolitinib |
JAK1, JAK2, TYK2 |
6 |
43 |
1.6563, 0.0237 |
3.4 |
4.51 |
-1.11 |
2 ** |
2.2 ** |
1.3 * |
2.63e-05 |
NA |
NA |
5.1 |
a7 |
gain_cnaBRCA26_(CDK12,ERBB2,MED24) |
1032 |
|
1 |
Afatinib |
ERBB2, EGFR |
15 |
30 |
-0.693 |
-1.18 |
1.03 |
-2.2 |
1.5 * |
1.5 * |
1.4 * |
3.54e-05 |
NA |
NA |
5.9 |
a8 |
loss_cnaBRCA34 |
1011 |
|
1 |
ABT-263 |
BCL2, BCL2L1, BCL2L2 |
5 |
38 |
0.693 |
-0.937 |
2.03 |
-2.96 |
2.2 ** |
2.2 ** |
1.6 * |
5.06e-05 |
NA |
NA |
7.3 |
a9 |
ASH1L_mut |
147 |
|
1 |
NSC-87877 |
PTPN6 (SHP-1), PTPN11 (SHP-2) |
3 |
44 |
2.77 |
2.94 |
5.15 |
-2.21 |
2.5 ** |
2.6 ** |
1.6 * |
1.08e-04 |
NA |
NA |
14 |
a10 |
gain_cnaBRCA47_(EGFR) |
1114 |
|
1 |
Cetuximab |
EGFR |
6 |
39 |
4.19 |
5.1 |
6.46 |
-1.37 |
1.8 * |
2.2 ** |
1 * |
1.42e-04 |
NA |
NA |
16 |
a11 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
180 |
|
1 |
Thapsigargin |
sarco-endoplasmic reticulum Ca2+-ATPases |
4 |
41 |
-0.669 |
0.617 |
-3.89 |
4.5 |
2.2 ** |
2.2 ** |
2.2 ** |
1.53e-04 |
NA |
NA |
16 |
a12 |
gain_cnaBRCA26_(CDK12,ERBB2,MED24) |
119 |
|
1 |
Lapatinib |
ERBB2, EGFR |
4 |
9 |
0.693 |
-1.31 |
2.66 |
-3.97 |
3.3 ** |
5.6 ** |
2 ** |
1.8e-04 |
NA |
NA |
16 |
a13 |
gain_cnaBRCA39_(FOXA1,NKX2-1,PSMA6) |
204 |
|
1 |
Tipifarnib |
Farnesyl-transferase (FNTA) |
7 |
41 |
2.77 |
3.48 |
1.3 |
2.18 |
1.7 * |
1.8 * |
1.2 * |
1.81e-04 |
NA |
NA |
16 |
a14 |
ASH1L_mut |
170 |
|
1 |
Shikonin |
unknown |
3 |
44 |
2.77 |
-2.3 |
0.161 |
-2.47 |
2.4 ** |
2.4 ** |
11 ** |
2.13e-04 |
NA |
NA |
18 |
a15 |
gain_cnaBRCA26_(CDK12,ERBB2,MED24) |
1003 |
|
1 |
Camptothecin |
TOP1 |
15 |
30 |
-2.3 |
-1.37 |
-3.11 |
1.73 |
1.3 * |
1.5 * |
1 . |
2.35e-04 |
NA |
NA |
18 |
a16 |
loss_cnaBRCA32_(PABPC3,SACS,ZMYM2) |
53 |
|
1 |
CGP-60474 |
CDK1,CDK2,CDK5,CDK7,CDK9 |
3 |
9 |
-1.36 |
0.442 |
-2.41 |
2.86 |
3.7 ** |
4.6 ** |
2.4 ** |
2.46e-04 |
NA |
NA |
18 |
a17 |
gain_cnaBRCA27_(CLTC,PPM1D) |
255 |
|
1 |
CP724714 |
ERBB2 |
9 |
39 |
2.33 |
2.08 |
4.2 |
-2.12 |
1.5 * |
1.9 * |
0.87 . |
2.62e-04 |
NA |
NA |
18 |
a18 |
loss_cnaBRCA33 |
312 |
|
1 |
AV-951 |
VEGFR |
6 |
42 |
-2.06 |
-0.207 |
0.752 |
-0.959 |
1.7 * |
1.8 * |
1.2 * |
2.85e-04 |
NA |
NA |
18 |
a19 |
loss_cnaBRCA32_(PABPC3,SACS,ZMYM2) |
41 |
|
1 |
S-Trityl-L-cysteine |
KIF11 |
3 |
9 |
1.63 |
3.53 |
0.457 |
3.07 |
3.5 ** |
3.4 ** |
4 ** |
3.38e-04 |
NA |
NA |
19 |
a20 |
POLR2B_mut |
1218 |
|
1 |
JQ1 |
BRD2, BRD3, BRD4 |
3 |
43 |
0 |
1.13 |
2.55 |
-1.42 |
2.3 ** |
2.3 ** |
3.9 ** |
3.39e-04 |
NA |
NA |
19 |
a21 |
loss_cnaBRCA32_(PABPC3,SACS,ZMYM2) |
88 |
|
1 |
MS-275 |
HDAC |
5 |
9 |
1.61 |
2.99 |
0.111 |
2.88 |
2.7 ** |
3.9 ** |
1.9 * |
3.91e-04 |
NA |
NA |
19 |
a22 |
gain_cnaBRCA31 |
1268 |
|
1 |
XAV 939 |
TNKS1 (tankyrase-1) |
15 |
32 |
1.61 |
4.33 |
3.35 |
0.985 |
1.2 * |
1.2 * |
1.3 * |
3.94e-04 |
NA |
NA |
19 |
a23 |
gain_cnaBRCA62 |
301 |
|
1 |
PHA-793887 |
CDK-pan |
10 |
38 |
2.33 |
1.38 |
3.33 |
-1.95 |
1.4 * |
1.5 * |
1 * |
4.12e-04 |
NA |
NA |
19 |
a24 |
gain_cnaBRCA48 |
235 |
|
1 |
QL-XII-47 |
BTK, BMX |
5 |
44 |
2.33 |
3.84 |
1.47 |
2.37 |
1.8 * |
1.8 * |
2 ** |
4.3e-04 |
NA |
NA |
19 |
a25 |
CDH1_mut |
150 |
|
1 |
Bicalutamide |
ANDR (androgen receptor) |
4 |
44 |
0.0237 |
1.77 |
2.85 |
-1.09 |
2 * |
1.9 * |
2.7 ** |
4.34e-04 |
NA |
NA |
19 |
a26 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
140 |
|
1 |
Vinorelbine |
Microtubules |
5 |
42 |
-2.75 |
-1.28 |
-3.88 |
2.59 |
1.8 * |
1.8 * |
2 * |
4.38e-04 |
NA |
NA |
19 |
a27 |
PTEN_mut |
1030 |
|
1 |
KU-55933 |
ATM |
5 |
37 |
2.3 |
2.94 |
4.39 |
-1.45 |
1.8 * |
1.8 * |
2.8 ** |
4.5e-04 |
NA |
NA |
19 |
a28 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
1375 |
|
1 |
Temozolomide |
DNA akylating agent |
5 |
41 |
3.4 |
6.87 |
5.78 |
1.09 |
1.8 * |
1.8 * |
1.5 * |
4.74e-04 |
NA |
NA |
19 |
a29 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
201 |
|
1 |
Epothilone B |
Microtubules |
5 |
43 |
-3.44 |
-1.71 |
-4.53 |
2.82 |
1.8 * |
1.8 * |
1.9 * |
5.01e-04 |
NA |
NA |
19 |
a30 |
ASH1L_mut |
167 |
|
1 |
OSU-03012 |
PDPK1 (PDK1) |
3 |
45 |
2.77 |
0.062 |
2.39 |
-2.33 |
2.2 ** |
2.3 ** |
1.8 * |
5.03e-04 |
NA |
NA |
19 |
a31 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
1268 |
|
1 |
XAV 939 |
TNKS1 (tankyrase-1) |
5 |
42 |
1.61 |
4.97 |
3.51 |
1.46 |
1.8 * |
1.8 * |
1.8 * |
5.27e-04 |
NA |
NA |
20 |
a32 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
167 |
|
1 |
OSU-03012 |
PDPK1 (PDK1) |
5 |
43 |
2.77 |
3.89 |
2.06 |
1.83 |
1.7 * |
1.8 * |
1.4 * |
5.71e-04 |
NA |
NA |
21 |
a33 |
gain_cnaBRCA39_(FOXA1,NKX2-1,PSMA6) |
184 |
|
1 |
BMS-754807 |
IGF1R |
7 |
41 |
0.94 |
3.54 |
1.3 |
2.24 |
1.5 * |
1.4 * |
2.5 ** |
6.15e-04 |
NA |
NA |
22 |
a34 |
loss_cnaBRCA18 |
275 |
|
1 |
I-BET |
BRD2, BRD3, BRD4 |
16 |
33 |
3 |
3.13 |
4.48 |
-1.35 |
1.1 * |
1.1 * |
1.3 * |
6.4e-04 |
NA |
NA |
22 |
a35 |
gain_cnaBRCA64_(SDHC) |
224 |
|
1 |
AS605240 |
PI3Kgamma |
8 |
41 |
3.00, 2.33 |
1.61 |
3.59 |
-1.98 |
1.4 * |
1.8 * |
0.78 . |
6.64e-04 |
NA |
NA |
22 |
a36 |
gain_cnaBRCA31 |
1526 |
|
1 |
RDEA119 (rescreen) |
MAP2K1 (MEK1), MAP2K2 (MEK2) |
13 |
30 |
1.61 |
4.07 |
2.46 |
1.61 |
1.2 * |
1.1 * |
1.9 * |
6.69e-04 |
NA |
NA |
22 |
a37 |
gain_cnaBRCA62 |
1057 |
|
1 |
NVP-BEZ235 |
PI3K (Class 1) and MTORC1/2 |
7 |
36 |
-1.386, 0.693 |
-1.16 |
-2.43 |
1.26 |
1.5 * |
1.6 * |
1.3 * |
6.89e-04 |
NA |
NA |
22 |
a38 |
gain_cnaBRCA30_(CRNKL1,FOXA2) |
1020 |
|
1 |
Lenalidomide |
TNFA |
5 |
40 |
1.61 |
5.22 |
4.13 |
1.08 |
1.7 * |
1.8 * |
1.4 * |
7.3e-04 |
NA |
NA |
22 |
a39 |
loss_cnaBRCA18 |
306 |
|
1 |
TG101348 |
JAK2 |
15 |
33 |
2.33 |
2.35 |
3.62 |
-1.28 |
1.1 * |
1 * |
1.4 * |
8.1e-04 |
NA |
NA |
24 |
a40 |
loss_cnaBRCA33 |
1011 |
|
1 |
ABT-263 |
BCL2, BCL2L1, BCL2L2 |
5 |
38 |
0.693 |
-0.548 |
1.98 |
-2.52 |
1.7 * |
1.7 * |
1.7 * |
8.19e-04 |
NA |
NA |
24 |
a41 |
gain_cnaBRCA27_(CLTC,PPM1D) |
293 |
|
1 |
MP470 |
PDGFR |
9 |
39 |
3 |
1.94 |
3.9 |
-1.96 |
1.3 * |
1.5 * |
0.97 . |
8.69e-04 |
NA |
NA |
25 |
a42 |
gain_cnaBRCA47_(EGFR) |
1010 |
|
1 |
Gefitinib |
EGFR |
7 |
38 |
-0.693 |
0.256 |
1.61 |
-1.35 |
1.5 * |
1.4 * |
1.6 * |
8.94e-04 |
NA |
NA |
25 |
